FXYD6
FXYD domain-containing ion transport regulator 6
Also known as: FXYD6_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9H0Q3
- Gene
- FXYD6
- Ensembl
- ENSG00000137726
- Chromosome
- 11
- Canonical length
- 95 aa
- Protein class
- Predicted membrane proteins, Transporters
- Subcellular location
- Nucleoplasm,Cytosol
OverviewNCBI Gene
This gene encodes a member of the FXYD family of transmembrane proteins. This particular protein encodes phosphohippolin, which likely affects the activity of Na,K-ATPase. Multiple alternatively spliced transcript variants encoding the same protein have been described. Related pseudogenes have been identified on chromosomes 10 and X. Read-through transcripts have been observed between this locus and the downstream sodium/potassium-transporting ATPase subunit gamma (FXYD2, GeneID 486) locus.[provided by RefSeq, Feb 2011]
Canonical amino-acid sequenceUniProt
95 residues, UniProt reviewed canonical sequence.
>Q9H0Q3|FXYD6
1 MELVLVFLCS LLAPMVLASA AEKEKEMDPF HYDYQTLRIG GLVFAVVLFS VGILLILSRR
61 CKCSFNQKPR APGDEEAQVE NLITANATEP QKAENLocalizationUniProt · AlphaFold · HPA
Whether an antibody against FXYD6 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.55
- Highest tissue expression
- 429 nTPM
Expression across tissuesHPA
Tissue
- cerebral cortex: 429 nTPM
- colon: 383 nTPM
- endometrium: 337 nTPM
- hypothalamus: 306 nTPM
- ovary: 293 nTPM
- cerebellum: 290 nTPM
Single-cell type
- hepatic stellate cells: 13 nCPM
- lymphatic endothelial cells: 6.3 nCPM
- peritubular myoid cells: 5.7 nCPM
- smooth muscle cells: 4.8 nCPM
- pericytes: 4.2 nCPM
- other brain neurons: 3.8 nCPM
Immune cell
- classical monocyte: 38 nTPM
- total PBMC: 9.9 nTPM
- intermediate monocyte: 9.4 nTPM
- myeloid DC: 6.3 nTPM
- neutrophil: 0.9 nTPM
- MAIT T-cell: 0.6 nTPM
Brain region
- basal ganglia: 525 nTPM
- cerebral cortex: 505 nTPM
- hypothalamus: 381 nTPM
- midbrain: 362 nTPM
- white matter: 358 nTPM
- pons: 311 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.65
- gnomAD pLI
- 0.62
- gnomAD missense Z
- 0.78
- DepMap mean gene effect
- 0.11
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- positive regulation of sodium ion export across plasma membrane
- potassium ion transport
- sodium ion transport
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads FXYD6 as an antibody target. Whether an autoantibody or antibody against FXYD6 could matter depends on whether native FXYD6 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
FXYD6 is annotated at the cell surface, where native FXYD6 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label FXYD6 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...